FDA Investigator Azeezat M Lawal
Azeezat M Lawal has conducted inspections on 5 sites in 1 countries as of 29 May 2024. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
5
Last Inspection Date:
29 May 2024
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America
FDA Investigators that have inspected at least one site in common with Azeezat M Lawal:
Barbara Jwilimczyk Macri,
Brooke K Higgins,
Catherine O Lamptey,
Chiang Syin, PhD,
Christian F Gomez Lugo,
Christina K Theodorou,
Craig D Zagata,
Daniel J Grabicki,
David A Oluwo,
Devon Jenkins,
Diane T Bargo,
Edward P Potter,
Emest F Bizjak,
Eric L Dong, BS,
Gale L Glinecki,
James W Leonette,
Johnny D Nwankwo,
Jonathan G Matrisciano,
Joseph L Despins, PhD,
Joseph W Matthews,
Joy Rkozlowski Klena,
Justine Tomasso,
Karen A Briggs,
Karen E D'orazio,
Keith M Reilly,
Krystyna M Kitson,
Latoya S Oliver Powell,
Loretta Nemchik,
Lori M Newman,
Marcus A Ray,
Marea K Harmon,
Margaret M Sands,
Melissa J Garcia,
Merideth K Rose,
Nancy M Espinal,
Nebil A Oumer,
Nelson N Ayangho,
Pamela N Agaba,
Paul L Bellamy,
Puspa Suresh Jayasekara,
Qin Xu,
Rachel C Harrington,
Rochelle L Cross,
Rosario D'costa,
Roseline N Boateng,
Russell J Glapion,
Sean R Marcsisin,
Sena G Dissmeyer,
Stacey A Priest,
Stephanie L Shapley,
Steven P Donald,
Suzanne M Healy,
Suzanne M Muchene,
Tamil Arasu, PhD,
Tekalign Wondimu,
William J Leonard,
Xiandong Meng,
Yaharn Su,
Yan Qin,
Yoriann M Cabrera Bartolomei,
Yvesna C Blaise,
Zhao Wang, PhD,
Zhong Li, PhD,
Zi Qiang Gu
Azeezat M Lawal's Documents
Publish Date | Document Type | Title |
---|---|---|
June, 2024 | FDA 483 | Hikma Pharmaceuticals USA Inc. - Form 483, 2024-06-12 |
December, 2023 | FDA 483 | Granules Pharmaceuticals Inc. - Form 483, 2023-12-15 |
February, 2024 | FDA 483 | Chempacific Corporation - Form 483, 2024-02-15 |
April, 2024 | FDA 483 | Eisai Inc. - Form 483, 2024-04-09 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more